A Multicenter Randomized Double-blind Clinical Study Evaluated the Safety, Pharmacokinetic and Pharmacodynamic Characteristics of Roflumilast in COPD Patients
Phase of Trial: Phase II
Latest Information Update: 29 Dec 2017
At a glance
- Drugs Roflumilast (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 23 Dec 2017 Planned End Date changed from 1 Aug 2017 to 1 Dec 2017.
- 23 Dec 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Dec 2017.
- 05 Apr 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.